A Change in the Trend of Quality Reporting in Leprosy Trials: A Systematic Review.

Q3 Pharmacology, Toxicology and Pharmaceutics
Pugazhenthan Thangaraju, Pranav G Sheth, Hemasri Velmurugan, Sajitha Venkatesan, Aravind Kumar B
{"title":"A Change in the Trend of Quality Reporting in Leprosy Trials: A Systematic Review.","authors":"Pugazhenthan Thangaraju,&nbsp;Pranav G Sheth,&nbsp;Hemasri Velmurugan,&nbsp;Sajitha Venkatesan,&nbsp;Aravind Kumar B","doi":"10.2174/1871526523666230224104113","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Leprosy is a communicable disease caused by bacteria Mycobacterium leprae. Despite all attempts, it has not been eradicated in several underdeveloped nations since the start of the antibiotic age. It's a social issue as well as a stigmatised disease. Due to these restrictions, randomised controlled trials in leprosy confront numerous obstacles, which are reflected in the quality of study reporting.</p><p><strong>Objectives: </strong>The objective of this study is to use the Consolidated Standard for Reporting Trials (CONSORT) 2010 checklist to assess the quality of leprosy trial reporting.</p><p><strong>Methods: </strong>We assess the quality of reporting of randomised control trials on leprosy conducted after 2010 in the PubMed database, using the CONSORT checklist 2010. Second, we compare the quality of RCT reporting before and after the release of the CONSORT guidelines in 2010.</p><p><strong>Results: </strong>A total of 19 full-text eligible articles were examined and included in the final list of articles, which were then evaluated further. 4 out of 19 trials had a compliance percentage of more than 75%. 6 out of 19 trials had compliance percentage of 50% to 75%. 9 trials had a compliance percentage of below 50%. Highest compliance was 86.48% and the lowest compliance was 32.43%. When compared with trials before 2010, we could see an improvement in some criteria showing a statistically significant rise in comparison with trials conducted before 2010.</p><p><strong>Conclusion: </strong>Leprosy is still a concern in developing countries, which have failed to eradicate the disease despite their best efforts and resources. The compliance of leprosy related RCTs has improved since the introduction of the CONSORT guidelines, but the quality of reporting still remains on the lower side.</p>","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":"23 4","pages":"e240223214010"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious disorders drug targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1871526523666230224104113","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Leprosy is a communicable disease caused by bacteria Mycobacterium leprae. Despite all attempts, it has not been eradicated in several underdeveloped nations since the start of the antibiotic age. It's a social issue as well as a stigmatised disease. Due to these restrictions, randomised controlled trials in leprosy confront numerous obstacles, which are reflected in the quality of study reporting.

Objectives: The objective of this study is to use the Consolidated Standard for Reporting Trials (CONSORT) 2010 checklist to assess the quality of leprosy trial reporting.

Methods: We assess the quality of reporting of randomised control trials on leprosy conducted after 2010 in the PubMed database, using the CONSORT checklist 2010. Second, we compare the quality of RCT reporting before and after the release of the CONSORT guidelines in 2010.

Results: A total of 19 full-text eligible articles were examined and included in the final list of articles, which were then evaluated further. 4 out of 19 trials had a compliance percentage of more than 75%. 6 out of 19 trials had compliance percentage of 50% to 75%. 9 trials had a compliance percentage of below 50%. Highest compliance was 86.48% and the lowest compliance was 32.43%. When compared with trials before 2010, we could see an improvement in some criteria showing a statistically significant rise in comparison with trials conducted before 2010.

Conclusion: Leprosy is still a concern in developing countries, which have failed to eradicate the disease despite their best efforts and resources. The compliance of leprosy related RCTs has improved since the introduction of the CONSORT guidelines, but the quality of reporting still remains on the lower side.

麻风病试验质量报告趋势的变化:一项系统评价。
背景:麻风是一种由麻风分枝杆菌引起的传染病。尽管做出了种种努力,但自抗生素时代开始以来,它在几个不发达国家仍未被根除。这是一个社会问题,也是一种耻辱性疾病。由于这些限制,麻风病的随机对照试验面临许多障碍,这反映在研究报告的质量上。目的:本研究的目的是使用2010年综合试验报告标准(CONSORT)清单来评估麻风病试验报告的质量。方法:我们使用2010年CONSORT检查表,评估PubMed数据库中2010年以后进行的麻风病随机对照试验的报告质量。其次,我们比较了2010年CONSORT指南发布前后RCT报告的质量。结果:共审查了19篇符合条件的全文文章,并将其纳入最终文章列表,然后对其进行进一步评估。19例试验中有4例的依从率大于75%。19项试验中有6项的依从率为50% ~ 75%。9个试验的依从率低于50%。最高合规率为86.48%,最低合规率为32.43%。与2010年之前的试验相比,我们可以看到一些标准的改善,与2010年之前进行的试验相比,统计上显着上升。结论:麻风病在发展中国家仍然是一个令人关注的问题,尽管他们尽了最大的努力和资源,但仍未能根除这种疾病。自引入CONSORT指南以来,麻风病相关随机对照试验的依从性有所改善,但报告的质量仍然较低。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Infectious disorders drug targets
Infectious disorders drug targets Pharmacology, Toxicology and Pharmaceutics-Pharmacology
CiteScore
3.10
自引率
0.00%
发文量
123
期刊介绍: Infectious Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in infectious disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in infectious disorders. As the discovery, identification, characterization and validation of novel human drug targets for anti-infective drug discovery continues to grow, this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信